To date, the NCCN Clinical Practice Guidelines for small cell lung cancer (SCLC) have not recommended routine testing for PD-L1 expression or tumor mutational burden (TMB), due to insufficient evidence linking these biomarkers with clinical benefit from immunotherapy. This evidence concerns the gene CD274 and small cell lung carcinoma.